- Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
-
Helm CW
- KMID: 2158795
- J Gynecol Oncol.
- 2015 Jan;26(1):1-2.
- doi: 10.3802/jgo.2015.26.1.1
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
-
Martin JY, Urban RR, Liao JB, Goff BA
- KMID: 2374249
- J Gynecol Oncol.
- 2016 Sep;27(5):e47.
- doi: 10.3802/jgo.2016.27.e47
OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy
-
Kwon YS, Nam JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT
- KMID: 1779203
- J Korean Med Sci.
- 2009 Aug;24(4):679-683.
- doi: 10.3346/jkms.2009.24.4.679
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between... -
- CITED
-
- Close
- SHARE
-
- Close
- ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
-
Lee M, Kim SW, Nam EJ, Cho H, Kim JH, Kim YT, Kim S
- KMID: 2070217
- Yonsei Med J.
- 2014 Nov;55(6):1664-1671.
- doi: 10.3349/ymj.2014.55.6.1664
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One... -
- CITED
-
- Close
- SHARE
-
- Close
- Pitfall in Chemotherapy for Ovarian Cancer
-
Kamura T, Kim YT
- KMID: 1093954
- Yonsei Med J.
- 2002 Dec;43(6):779-782.
- doi: 10.3349/ymj.2002.43.6.779
Concerning the biological properties of recurrent ovarian cancer, other than drug resistance, we revealed that the expressions of mutant p53 and CD44v6 genes were significantly greater in recurrent ovarian cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
-
Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS
- KMID: 2413200
- J Gynecol Oncol.
- 2017 Nov;28(6):e73.
- doi: 10.3802/jgo.2017.28.e73
OBJECTIVE: The chemotherapy response score (CRS) system based on histopathological examination has been recently proposed for tubo-ovarian high-grade serous carcinoma (HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study... -
- CITED
-
- Close
- SHARE
-
- Close
- Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin
-
Zhao H, Yang Z, Wang X, Zhang X, Wang M, Wang Y, Mei Q, Wang Z
- KMID: 1401755
- Exp Mol Med.
- 2012 Nov;44(11):633-641.
Triptolide, a compound extracted from the traditional Chinese medicine preparation of Tripterygium wilfordii Hook F., has been reported to have anti-inflammatory and anti-cancer activities. However, its effect on ovarian cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
-
Kang H, Kim TJ, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG
- KMID: 1782020
- J Korean Med Sci.
- 2009 Oct;24(5):945-950.
- doi: 10.3346/jkms.2009.24.5.945
The aim of this trial was to investigate the efficacy and toxicity of combination chemotherapy with etoposide and ifosfamide (ETI) in the management of heavily pretreated recurrent or persistent epithelial... -
- CITED
-
- Close
- SHARE
-
- Close
- An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
-
Lee SW, Kim YM, Kim YT, Kang SB
- KMID: 2413442
- J Gynecol Oncol.
- 2017 May;28(3):e26.
- doi: 10.3802/jgo.2017.28.e26
OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This... -
- CITED
-
- Close
- SHARE
-
- Close
- Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell
-
Lee HG, Shin SJ, Chung HW, Kwon SH, Cha SD, Lee JE, Cho CH
- KMID: 2413456
- J Gynecol Oncol.
- 2017 Mar;28(2):e14.
- doi: 10.3802/jgo.2017.28.e14
OBJECTIVE: Cancer stem cells (CSCs) represent a subpopulation of undifferentiated tumorigenic cells thought to be responsible for tumor initiation, maintenance, drug resistance, and metastasis. The role of CSCs in drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-Proliferative and Apoptotic Activities of Mullerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines
-
Jung YS, Kim HJ, Seo SK, Choi YS, Nam EJ, Kim S, Kim SW, Han HD, Kim JW, Kim YT
- KMID: 2466349
- Yonsei Med J.
- 2016 Jan;57(1):33-40.
- doi: 10.3349/ymj.2016.57.1.33
PURPOSE: This study aimed to investigate whether Mullerian inhibiting substance (MIS) in combination with calcitriol modulates proliferation and apoptosis of human ovarian cancer (OCa) cell lines (SKOV3, OVCAR3, and OVCA433)... -
- CITED
-
- Close
- SHARE
-
- Close
- Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
-
Coccolini , Campanati , Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum , Ansaloni L
- KMID: 2158803
- J Gynecol Oncol.
- 2015 Jan;26(1):54-61.
- doi: 10.3802/jgo.2015.26.1.54
OBJECTIVE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recently reported with favorable oncological outcomes as treatment of advanced epithelial ovarian cancer (EOC). The aim of this study... -
- CITED
-
- Close
- SHARE
-
- Close
